{"denoms":[{"counts":[{"groupId":"OG000","value":"0"}],"units":"Participants"}],"description":"This endpoint will evaluate the correlation between intensity of CD38 expression (percentage of expression) and response to the treatment. The extent of CD38 expression evaluated by the central designed laboratory of FIL (Fondazione Italiana Linfomi) will be performed on fresh sections cut from the paraffin block (or on unstained sections), and the percentage of positive tumor cells will be scored according to Bossard C. et al as follows: 4: \\>75%; 3: 50-75%; 2: 25-49%; 1: 5-24%; 0: \\<5%. The percentage of CD38 expression will be correlated with response measured according to the Lugano 2014 criteria","groups":[{"description":"Daratumumab in combination with Gemcitabine, Dexamethasone and Cisplatin (D-GDP) in patients with relapsed/refractory CD38 positive peripheral T-cell lymphoma not otherwise specified (PTCL-NOS), angioimmunoblastic T-cell lymphoma (AITL) and other nodal lymphomas of TFH cell origin.","id":"OG000","title":"One Arm"}],"populationDescription":"No data displayed because Outcome Measure has zero total participants analyzed. So, data were not collected.","reportingStatus":"POSTED","timeFrame":"The endpoint will be assessed from the start date of therapy to the end of the first four cycle of therapy (cycles of 21 days) and at each restaging through study completion, up to 26 months.","title":"Percentage of CD38 Expression in Correlation With the Response to the Treatment","type":"OTHER_PRE_SPECIFIED"}